The Medical Research Council and the National Institute for Health and Care Research recently published a Rare Diseases Research Landscape Project Report. Read more
Today (Wednesday 20th September), Filsuvez®, the gel developed by Amryt Pharma, successfully passed the appeal process. Read more
In National Eye Health Week, we’re highlighting the projects we fund that aim to provide relief from eye symptoms of EB. Read more
DEBRA UK is pleased to announce that it has approved its first drug repurposing clinical trial which has been made possible with funding raised through the A Life Free of Pain appeal. Read more
We are delighted to hear that Filsuvez®, the gel developed by Amryt Pharma as a treatment to promote the healing of partial thickness wounds has now been approved for use in the UK by the National Institute for Health Care and Excellence (NICE). Read more
Find out more about the research projects and how they could improve the quality of life for people living with EB. Read more
Once available, VYJUVEK will be the first-ever redosable gene therapy for treatment of DEB. Read more
DEBRA UK is pleased to announce it has agreed a new partnership with AMRC to support their research into finding effective treatments for children living with epidermolysis bullosa simplex (EBS). Read more
Members of DEBRA’s senior management team visited the Blizard Institute at the Queen Mary University of London to hear about the EB research projects they are working on. Read more
We’re delighted to announce that we have awarded funding to three exciting new research projects. Read more
#RareDiseaseDay, is a day dedicated to raising awareness and generating change for people worldwide living with a rare disease, their families and carers. Read more
On Thursday 5th January, our Senior Management Team and trustees were welcomed to the University of Birmingham and School of Dentistry to observe the incredible DEBRA-funded research projects taking place there. Read more
We are delighted to announce that the "Hand surgery and hand therapy clinical practice guideline for epidermolysis bullosa has been published. Read more
DEBRA UK is now a member of two important associations that can help support us in raising awareness and understanding of EB, GlobalSkin and Genetic Alliance UK. Read more
Another potential treatment for Recessive Dystrophic EB (RDEB) is one step closer with the recent news that Abeona Therapeutics have completed their patient clinical trials of their engineered cell therapy, EB-101. Read more
We are pleased to report that Filsuvez®, the gel developed by Amryt Pharma, has been approved by the MHRA for use in Great Britain. Read more